Page last updated: 2024-09-03

rb 6145 and Sarcoma

rb 6145 has been researched along with Sarcoma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ali, M; Babur, M; Bloomer, WD; Cawthorne, C; Julyan, PJ; Lunt, SJ; Papadopoulou, MV; Price, PM; Smigova, A; Stratford, IJ; Telfer, BA; Williams, KJ1
Adams, GE; Bedwell, J; Bown, SG; Bremner, JC; MacRobert, AJ; Pearson, JK; Phillips, D; Sansom, JM; Stratford, IJ1

Other Studies

2 other study(ies) available for rb 6145 and Sarcoma

ArticleYear
The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.
    British journal of cancer, 2010, Jul-13, Volume: 103, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation, Preclinical; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred C3H; Neoplasm Metastasis; Nitroimidazoles; Quinolines; Sarcoma; Tirapazamine; Triazines

2010
Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.
    British journal of cancer, 1992, Volume: 66, Issue:6

    Topics: Animals; Indoles; Mice; Misonidazole; Nitroimidazoles; Organometallic Compounds; Photochemotherapy; Sarcoma; Tumor Cells, Cultured

1992